American Society of Hematology

Fig. 2.

$Fig. 2. Survival data in 119 patients with recurrent or refractory HD treated with high-dose therapy and autografting. (A) Overall survival: at 4 years 52% (CI 41% to 63%) of patients are projected to be alive. (B) Freedom from progression: At 4 years 62% (CI 51% to 72%) of patients are projected to be free of progressive HD. (C) Event-free survival: At 4 years 48% (CI 38% to 59%) of patients are projected to be alive and disease-free.$

Survival data in 119 patients with recurrent or refractory HD treated with high-dose therapy and autografting. (A) Overall survival: at 4 years 52% (CI 41% to 63%) of patients are projected to be alive. (B) Freedom from progression: At 4 years 62% (CI 51% to 72%) of patients are projected to be free of progressive HD. (C) Event-free survival: At 4 years 48% (CI 38% to 59%) of patients are projected to be alive and disease-free.

This Feature Is Available To Subscribers Only